New Stock Option Grants for Employees at Syndax Pharmaceuticals
NEW YORK, March 05, 2025 – Syndax Pharmaceuticals (NASDAQ: SNDX), a leading biopharmaceutical company focused on advancing groundbreaking cancer therapies, has recently disclosed exciting news for its team. On March 1, 2025, the company awarded stock options that allow purchases of up to 282,000 shares of common stock to twelve new employees. This initiative is part of Syndax's 2023 Inducement Plan aimed at strengthening its workforce to further their mission of revolutionizing cancer treatment.
Details of the Stock Options Grant
The granted stock options are structured to vest over a four-year period. Initially, 25% of the awarded shares will become available after one year from the commencement date, followed by a monthly vesting schedule where 1/48th of the shares will vest for the following 36 months. This vesting schedule is contingent upon the employee maintaining a service relationship with Syndax, promoting employee loyalty and retention as they contribute to the company's innovative pipeline.
The Innovative Pipeline of Syndax Pharmaceuticals
Syndax Pharmaceuticals boasts a unique portfolio of cancer therapies that are at various stages of development. Their flagship drug, Revuforj (revumenib), is an FDA-approved menin inhibitor that is making strides in cancer treatment. Additionally, Niktimvo™ (axatilimab-csfr), another notable asset in their pipeline, is an FDA-approved monoclonal antibody designed to inhibit the colony stimulating factor 1 receptor, a crucial factor in tumor growth.
Commitment to Cancer Care
The company is committed to pushing the boundaries of cancer care, continuously exploring new frontiers with their diverse pipeline. Syndax is currently engaged in several clinical trials aimed at enhancing therapeutic options for patients, reflecting their focus on research and development. The organization believes in reimagining cancer treatment by unlocking the potential of their innovative therapies, which can significantly impact patient outcomes.
Company Overview
Syndax Pharmaceuticals is not just a commercial-stage biopharmaceutical company; it embodies the spirit of innovation in the fight against cancer. By focusing on therapies that specifically target cancer cells, Syndax actively works to improve the lives of patients battling this formidable disease.
Engaging with the Community
To stay connected with their evolving narrative, Syndax encourages those interested to learn more through their website and social media platforms. Their online presence provides valuable information and updates regarding their ongoing clinical trials, future therapies, and overall commitment to advancing cancer care.
Frequently Asked Questions
What is the purpose of the stock options grant?
The stock options are granted to incentivize and reward new employees, fostering loyalty and encouraging long-term commitment to the company's goals.
How will the vesting of the stock options work?
The options will vest over four years, starting with 25% availability after one year and the remainder vesting monthly thereafter over 36 months.
What are the key therapies being developed by Syndax?
Syndax is developing innovative therapies including Revuforj (revumenib) and Niktimvo™ (axatilimab-csfr), both of which have received FDA approval.
How does Syndax engage with its community?
Syndax maintains an active presence online through its website and social media, offering updates and insights into clinical developments and patient care initiatives.
Who can be contacted for more information about Syndax?
For inquiries, individuals can reach out to Sharon Klahre via email at sklahre@syndax.com or by phone at 781.684.9827.
